Trial reportClinical journal of the American Society of Nephrology : CJASN2010
Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.
Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00921570 (The Effects of Renin Angiotensin System Blockage), which is not on this map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combine Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.Chinese medical journal · 2016Pooled it
- Pooled it
- Angiotensin II receptor blockers improve peripheral endothelial function: a meta-analysis of randomized controlled trials.PloS one · 2014Pooled it
- The Effect of Corrected Inflammation, Oxidative Stress and Endothelial Dysfunction on Fmd Levels in Patients with Selected Chronic Diseases: A Quasi-Experimental Study.Scientific reports · 2020Trial
- Functional vascular study in hypertensive subjects with type 2 diabetes using losartan or amlodipine.Arquivos brasileiros de cardiologia · 2014Trial
- TWEAK-Fn14: a promising target for cardio-cerebrovascular diseases and brain-heart syndrome.Frontiers in immunology · 2025Review
- A Comprehensive Review of Clinical Studies Applying Flow-Mediated Dilation.Diagnostics (Basel, Switzerland) · 2024Review
- Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy.International journal of molecular sciences · 2020Review
- Postmortem plasma pentraxin 3 is a useful marker of fatal acute coronary syndrome.Scientific reports · 2019Article
- Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.Toxins · 2018Review
- The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension.Irish journal of medical science · 2017Article
- Association of Pentraxin 3 Gene Polymorphisms with Susceptibility to Diabetic Nephropathy.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Angiotensin receptor blockers & endothelial dysfunction: Possible correlation & therapeutic implications.The Indian journal of medical research · 2016Review
- TWEAK/Fn14 Axis: A Promising Target for the Treatment of Cardiovascular Diseases.Frontiers in immunology · 2014Review
- Biology of human pentraxin 3 (PTX3) in acute and chronic kidney disease.Journal of clinical immunology · 2013Review
- Evaluation of the association of plasma pentraxin 3 levels with type 2 diabetes and diabetic nephropathy in a Malay population.Journal of diabetes research · 2013Article
- Impact of antihypertensive drugs on TNF-like weak inducer of apoptosis.Clinical rheumatology · 2012Article
- Amlodipine Reduces Inflammation despite Promoting Albuminuria in the Streptozotocin-Induced Diabetic Rat.Nephron extra · 2012Article
- The effect of antihypertensive drugs on endothelial function as assessed by flow-mediated vasodilation in hypertensive patients.International journal of vascular medicine · 2012Article
- Host-protective effect of circulating pentraxin 3 (PTX3) and complex formation with neutrophil extracellular traps.Frontiers in immunology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesSoluble TNF-like weak inducer of apoptosis (sTWEAK) and long pentraxin-3 (PTX3) concentrations have been associated with endothelial function in patients with chronic kidney disease (CKD). This study tested the hypothesis that the improvement in endothelial function after initiation of angiotensin II receptor blocker (valsartan), calcium channel blocker (amlodipine) therapy, or a combination of both is directly linked to the normalization of sTWEAK and PTX3. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: One-hundred-eight diabetic CKD stage I patients with hypertension (56% men, 46.7+/-5.3 years) were allocated to a 12-week intervention with amlodipine (10 mg/d), valsartan (160 mg/d), or their combination. Plasma levels of sTWEAK, PTX3, and flow-mediated dilation (FMD) were studied during the interventions.
resultsAll treatment strategies effectively increased FMD and reduced proteinuria, confirming a more prone reduction with the combined therapy. These improvements were followed by significant PTX3 reductions. Valsartan alone and in combination with amlodipine achieved significant incremental raises in sTWEAK plasma levels. More importantly, the changes observed in sTWEAK (beta=0.25, P=0.006) or PTX3 (beta=-0.24, P=0.007) plasma levels were independently associated with the improvement in ultrasonographically measured FMD.
conclusionsThis study shows that treatment with antihypertensive drugs improves FMD and normalizes proteinuria, PTX3, and sTWEAK in diabetic CKD stage I patients with hypertension. The improvement in FMD was independently associated with PTX3 and sTWEAK normalization. Two surrogate biomarkers of endothelial function are therefore identified with potential as therapeutic targets. The study was registered in clinicaltrials.gov as NCT00921570.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.